Company overview
ProBioGen AG is a Berlin-based CDMO specializing in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals including proteins, antibodies, viral vectors, and vaccines. They offer proprietary technologies like GlymaxX® for afucosylated antibodies enhancing ADCC efficacy. Services are supported by a GMP-compliant quality system meeting EMA/FDA standards with up to 1000L bioreactor capacity.
ProBioGen AG is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include probiogen, cdmo, cell line engineering, gmp manufacturing, biopharmaceuticals, glymaxx.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with ProBioGen AG include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.probiogen.de
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- probiogen, cdmo, cell line engineering, gmp manufacturing, biopharmaceuticals, glymaxx, viral vectors
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What CDMO services does ProBioGen provide?
- Cell line engineering with media optimization, upstream/downstream process development, GMP and non-GMP manufacturing of proteins, antibodies, viral vectors, and vaccines, plus analytical services including cell-based bioassays.
- What regulatory standards does ProBioGen comply with?
- All services follow international ISO and GMP standards compliant with EMA/FDA requirements, embedded in a total quality management system.
- Where is ProBioGen located and what are their manufacturing capabilities?
- Based in Berlin, Germany, with 30+ years experience; offers scalable GMP manufacturing up to 1000L bioreactors for biopharmaceuticals.
Related editorial coverage
- America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
- AI Citation Gap in CDMO Capacity: Pharmaceutical Manufacturing Examples and Insights
- HHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134
- CordenPharma Expands Production Capacity with New CDMO Deal
- Novartis Ends Contract with Porton: Legal Implications and Market Impact
- ASGCT 2026: Manufacturing Innovations Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
